抗汉滩病毒鼠/人嵌合抗体工程细胞的驯化、抗体表达及鉴定

目的:通过对稳定表达抗汉滩病毒鼠/人嵌合抗体的CHO细胞进行驯化,检测其抗体的表达情况,并对所表达抗体的生物学活性进行初步鉴定。方法:将本课题组前期筛选得到的稳定高表达细胞株1-D9进行无血清驯化,使其适合悬浮培养后接种到摇瓶,通过调整不同的培养条件,每天检测细胞的活率和抗体表达量,并对表达的抗体进行生物学活性鉴定。结果:通过驯化得到了适合悬浮培养的CHO细胞株,其抗体表达量高,生产周期短;并优化了其悬浮培养条件,表达的抗体经鉴定其生物学活性稳定。结论:优化了抗汉滩病毒鼠/人嵌合抗体表达条件,为下一步工业化生产提供了实验依据。     

用三步法纯化重组人促红细胞生成素

在生物反应器中培养中国仓鼠卵巢细胞—促红细胞生成素(CHO-EPO)C2细胞株,培养上清液中重组人促红细胞生成素(rHuEPO)表达水平达2000～3000U/ml。培养上清经过三步纯化:第一步为反相柱色谱,可将样品浓缩约96.7％,其收集液经充分透析后进行第二步的DEAE-离子交换色谱,最后进行分子筛色谱,总回收率为30％以上,经纯化的rHuEPO比活性为1.5×10~8U/g蛋白,SDSPAGE一条带,扫描测试纯度达98％以上。     

人血清白蛋白-干扰素α2b融合蛋白在CHO细胞中的表达

干扰素α2b(interferonα2b,IFNα2b)是一种用于病毒性疾病和肿瘤性疾病治疗的多功能细胞因子,因其在体内的半衰期短限制了其在临床上的应用。将IFNα2b连接到人血清白蛋白(human serum albumin,HSA)的C端,构建融合蛋白HSA-IFNα2b。构建含融合蛋白的真核表达质粒p MH3/HSA-IFNa2b,经电转的方法转入中国仓鼠卵巢(Chinese hamster ovary,CHO)细胞中。经G418抗性压力筛选和目的蛋白的表达量筛选,最终获得一株高表达的稳定细胞株(CHO/p MH3/HSA-IFNa2b)。表达的目的蛋白经Western blot验证显示,产物具有IFNα2b和HSA的双抗原性。经悬浮驯化稳定后,通过批次筛选得到一株稳定的高克隆表达株,产量约为65mg/L,进一步选取高表达克隆株在悬浮驯化中不同代数进行批次培养,不同代数之间蛋白质的表达量和生长情况没有明显的差异,获得一株稳定遗传表达的单克隆细胞株,3L摇瓶的流加培养结果显示,最佳发酵时间为15天,蛋白质表达量为121mg/L。经离心获得的发酵液,经两步纯化后获得蛋白质纯度高达96.8%的目的蛋白,总回收率为22.3%。参照《中国药典》2015版对IFNα2b的检测方法,结果显示,CHO表达的HSA-IFNα2b比活性为4.16×106IU/mg。首次将HSA-IFNα2b在哺乳动物细胞CHO中构建表达,表达获得高活性的HSA-IFNα2b融合蛋白。     

人EPO高效表达细胞株的筛选与鉴定

用氨甲喋呤 (MTX)对稳定转染人促红细胞生成素 (EPO)基因的CHOˉ(DHFR缺陷型 )细胞株进行梯度加压 ,并使用α -MEM培养基进行培养 ,使DHFR基因在CHOˉ细胞中大量扩增 ,从而使EPO的表达量提高。经检测分析EPO的表达量 ,筛选出EPO高效表达的细胞株。结果表明 ,用MTX加压到 16× 10 - 7mol l和 6 4× 10 - 7mol l浓度时 ,收集的细胞培养液经 (NH4 ) 2 SO4 盐析、透析等处理得到EPO抽提液 ,经SDS -聚丙烯酰胺凝胶电泳 (SDS -PAGE)检测出与标准品相对应的一条带 ,WesternBlot证明该带确为EPO。     

适于无血清贴壁培养的抗凋亡宿主细胞系CHO-IVB2的构建

应用无血清培养基培养CHO细胞时,由于没有血清提供各种贴壁因子,细胞以悬浮的方式生长。在实际的大规模细胞培养中,CHO细胞往往以贴壁方式培养,要么贴壁于悬浮的微载体中,要么贴壁于固定的聚酯盘状介质或中空纤维中,而很少直接悬浮于培养基中。在无血清培养基中,Vitronectin单一组分可以促使CHO细胞的贴壁和扩增。通过双表达lgf-1和Bcl-2基因,已经构建了可以在无蛋白培养基IMEM中抗凋亡生长的细胞株CHO-IB3。在此基础上,构建了可以同时表达Igf-1、Vitronectin和Bcl-2三个蛋白的三顺反子表达载体pCI—NII—IVB。将该载体转染于CHO—dhfr^-细胞中,构建了一个细胞株CHO—IVB2。该细胞株可以在无蛋白培养基中抗凋亡生长,适于以贴壁的方式大规模培养,用于大量生产外源目的蛋白。     

CHO细胞表达系统研究进展

CHO细胞表达系统是目前重组糖蛋白生产的首选系统。随着无血清悬浮培养技术、基因工程技术和大规模培养技术的应用和不断发展,CHO细胞表达系统已经成为生物技术药物最重要的表达或生产系统,并被广泛应用于抗体、重组蛋白药物和疫苗等产品的研发和生产中。近年来,针对CHO细胞表达系统在某些重组蛋白的表达和大规模生产中存在的不足,研究者们通过利用基因工程技术手段,结合重组蛋白表达机制的研究成果,为优化和应用CHO细胞表达系统做出了不懈努力。从培养基的优化、高产重组CHO细胞株的构建、大规模培养三个方面综述了CHO细胞表达系统的最近研究进展,以期为CHO细胞表达系统的研究与应用提供参考。     

制备可溶性肿瘤坏死因子受体II－脂联素球部融合蛋白的两种细胞培养工艺比较

利用7.5 L生物反应器篮式贴壁培养和全悬浮批式培养CHO工程细胞株表达可溶性肿瘤坏死因子受体Ⅱ-脂联素球部(sTNFRⅡ-gAD)融合蛋白,比较这两种培养方法的产率,以便优化高效表达sTNFRⅡ-gAD融合蛋白的制备工艺.篮式贴壁培养首先小规模培养CHO工程细胞株,待细胞增殖到一定密度后以3× 105～4× 105 cells/mL密度接种生物反应器贴壁培养3d,调换成不含血清的LK021培养基继续培养4d.而全悬浮无血清批式培养则以3×105～4×105 cells/mL密度的CHO工程细胞株接种于生物反应器,连续培养7d.培养过程实时监测培养条件,维持pH和DO的稳定.分别收集细胞上清,离心去细胞后用Pellicon切相流超滤系统对蛋白进行浓缩,并通过DEAE离子交换柱进行纯化.结果显示,篮式贴壁培养和全悬浮批式培养均成功表达了sTNFRⅡ-gAD融合蛋白,产量分别为8.0 mg/L和7.5 mg/L、纯度分别为95％和98％,从而为sTNFRⅡ-gAD融合蛋白的中试工艺研究提供了一定的基础.     

适于无血清贴壁培养的抗凋亡宿主细胞系CHO-IVB2的构建

应用无血清培养基培养CHO细胞时 ,由于没有血清提供各种贴壁因子 ,细胞以悬浮的方式生长。在实际的大规模细胞培养中 ,CHO细胞往往以贴壁方式培养 ,要么贴壁于悬浮的微载体中 ,要么贴壁于固定的聚酯盘状介质或中空纤维中 ,而很少直接悬浮于培养基中。在无血清培养基中 ,Vitronectin单一组分可以促使CHO细胞的贴壁和扩增。通过双表达Igf_1和Bcl_2基因 ,已经构建了可以在无蛋白培养基IMEM中抗凋亡生长的细胞株CHO_IB3。在此基础上 ,构建了可以同时表达Igf-1、Vitronectin和Bcl-2三个蛋白的三顺反子表达载体pCI-NII-IVB。将该载体转染于CHO-dhfr^- 细胞中 ,构建了一个细胞株CHO-IVB2。该细胞株可以在无蛋白培养基中抗凋亡生长 ,适于以贴壁的方式大规模培养 ,用于大量生产外源目的蛋白.     

重组人促红细胞生成素研究成果通过专家鉴定

重组人促红细胞生成素(EPO)是调节和维持红细胞生理循环的重要激素,对慢性肾性贫血有特效,并有可能在癌症、血液系统恶变、AIDS病等疾病所致的贫血治疗中开拓广泛的临床应用领域。目前国内使用的EPO制剂基本上全部从美国Amgen公司进口,为此每年要支付巨额外汇。我国促红细胞生成素的研究起步较晚,第二军医大学分子遗传学教研室在上海市科委的支持下,从1991年开始进行重组人促红细胞生成素高表达CHO细胞株     

稳定表达人Siat7e基因的MDCK细胞系的建立和全悬浮细胞的驯化

目的:现有的禽流感疫苗生产的方法已经不能适应工业化大生产的需求,有必要开发全悬浮培养的细胞系来满足大生产的需求。方法:我们通过转染稳定表达 Siat7e 基因的真核表达载体对MDCK细胞进行改造,并经过后期的驯化,筛选适应于全悬浮培养的MDCK细胞。结果:成功筛选到能稳定表达 Siat7e 基因并能适应全悬浮生长的细胞系。结论:该细胞系具有潜在的应用价值,为MDCK细胞的培养以及工业化大生产疫苗提供参考。     

类弹性蛋白多肽的从头设计、非色谱纯化及盐效应

近年来,因病毒侵害人类每年都要蒙受巨大的经济损失和社会损失。犬肾细胞MDCK以其具有的培养容易、增殖快、流感病毒感染效率高等特点,成为适用于流感病毒疫苗生产的重要细胞系之一。以MDCK细胞为研究对象,在自制无血清培养基中成功实现了MDCK细胞从有血清培养到无血清培养的驯化;并通过单细胞悬浮培养驯化过程实现了MDCK细胞的无血清单细胞悬浮培养,获得了适于无血清单细胞悬浮生长的ssf-MDCK细胞株,无血清单细胞悬浮批培养最大活细胞密度可达3.81×106 cells/mL,最大比生长速率可达0.056 h?     

Enhancement of recombinant human EPO production and glycosylation in serum-free suspension culture of CHO cells through expression and supplementation of 30Kc19

We previously reported that the expression of Bombyx mori 30Kc19 gene in CHO cells significantly improved both the production and sialylation of recombinant human EPO (rHuEPO) in adhesion culture mode. In this study, the effects of 30Kc19 expression and supplementation of 30Kc19 recombinant protein on the productivity and glycosylation pattern of rHuEPO were investigated in the serum-free suspension culture mode. Especially, glycosylation pattern was examined in detail using a quantitative MALDI-TOF MS method. The expression of 30Kc19 increased the EPO production by 2.5-folds and the host cells produced rHuEPO with more complex glycan structures and a larger content of sialic acid and fucose. The glycan structures of rHuEPO in the 30Kc19-expressing cell consisted of bi-, tri-, tetra-, and penta-antennary branching (35, 18, 33, and 14?%, respectively), while the control cells produced predominantly bi-antennary branching (70?%). About 53?% of the glycans from rHuEPO in the 30Kc19-expressing cell was terminally sialylated, while no obvious sialylated glycan was found in the control cells. The percentage of fucosylated glycans from the 30Kc19-expressing cell culture was 77?%, whereas only 61?% of the glycans from the control cell were fucosylated glycans. We also examined whether these effects were observed when the recombinant 30Kc19 protein produced from Escherichia coli was supplemented into the culture medium for CHO cells. In the control cell line without the 30Kc19 gene, EPO production increased by 41.6?% after the addition of 0.2?mg/mL of the recombinant 30Kc19 protein to the culture medium. By the Western blot analysis after two-dimensional electrophoresis (2-DE) of isoforms of EPO, we confirmed that 30Kc19 enhanced the sialylation of EPO glycans. These results demonstrated that both 30Kc19 gene expression and the recombinant 30Kc19 protein addition enhanced rHuEPO productivity and glycosylation in suspension culture. In conclusion, the utilization of 30Kc19 in CHO cell culture holds great promise for use in the manufacturing of improved biopharmaceutical glycoproteins.     

Comparison of fluidized bed and ultrasonic cell-retention systems for high cell density mammalian cell culture

Economically viable biopharmaceutical production is to a high degree dependent on high product yields and stable fermentation systems that are easy to handle. In the current study we have compared two different fermentation systems for the production of recombinant protein from CHO cells. Both systems are fully scaleable and can be used for industrial high cell density bioprocesses. As a model cell line we have used a recombinant CHO cell line producing the enzyme arylsulfatase B (ASB). CHO cells were cultivated as adherent cell culture attached on Cytoline macroporous microcarrier (Amersham Biosciences, Sweden) using a Cytopilot Mini fluidized bed bioreactor (FBR, Vogelbusch-Amersham Biosciences, Austria) and as suspension culture using a stirred tank bioreactor equipped with a BioSep ultrasonic resonator based cell separation device (Applikon, The Netherlands). Both systems are equally well-suited for stable, long-term high cell density perfusion cell culture and provide industrial scalability and high yields. For products such as the recombinant ASB, high perfusion rates and therefore short product bioreactor residence times may be of additional benefit.     

Stable expression of recombinant human coagulation factor XIII in protein-free suspension culture of Chinese hamster ovary cells

The recombinant a and bsubunits for human coagulation factor XIII were transfected into Chinese hamster ovary (CHO) cells. CHO cells were amplified and selected with methotrexate in adherent cultures containing serum, and CHO 1-62 cells were later selected in protein-free medium. To develop a recombinant factor XIII production process in a suspension culture, we have investigated the growth characteristics of CHO cells and the maintenance of factor XIII expression in the culture medium. Suspension adaptation of CHO cells was performed in protein-free medium, GC-CHO-PI, by two methods, such as serum weaning and direct switching from serum containing media to protein-free media. Although the growth of CHO cells in suspension culture was affected initially by serum depletion, cell specific productivity of factor XIII showed only minor changes by the direct switching to protein-free medium during a suspension culture. As for the long-term stability of factor XIII, CHO 1-62 cells showed a stable expression of factor XIII in protein-free condition for 1000 h. These results indicate that the CHO 1-62cells can be adapted to express recombinant human factor XIII in a stable maimer in suspension culture using a protein-free medium. Our results demonstrate that enhanced cell growth in a continuous manner is achievable for factor XIII production in a protein-free medium when a perfusion bioreactor culture system with a spin filter is employed. This revised version was published online in August 2006 with corrections to the Cover Date.     

Design of serum-free medium for suspension culture of CHO cells on the basis of general commercial media

The design of serum-free media for suspension culture of genetically engineered Chinese hamster ovary (CHO) cells using general commercial media as a basis was investigated. Subcultivation using a commercial serum-free medium containing insulin-like growth factor (IGF)-1 with or without FCS necessitated additives other than IGF-1 to compensate for the lack of FCS and improve cell growth. Suspension culture with media containing several combinations of growth factors suggested the effectiveness of addition of both IGF-1 and the lipid signaling molecule lysophosphatidic acid (LPA) for promoting cell growth. Subcultivation of CHO cells in suspension culture using the commercial serum-free medium EX-CELL™302, which contained an IGF-1 analog, supplemented with LPA resulted in gradually increasing specific growth rate comparable to the serum-containing medium and in almost the same high antibody production regardless of the number of generations. The culture with EX-CELL™302 supplemented with LPA in a jar fermentor with pH control at 6.9 showed an apparently higher cell growth rate than the cultures without pH control and with pH control at 6.8. The cell growth in the medium supplemented with aurintricarboxylic acid (ATA), which was much cheaper than IGF-1, in combination with LPA was synergistically promoted similarly to that in the medium supplemented with IGF-1 and LPA. In conclusion, the serum-free medium designed on the basis of general commercial media could support the growth of CHO cells and antibody production comparable to serum-containing medium in suspension culture. Moreover, the possibility of cost reduction by the substitution of IGF-1 with ATA was also shown.     

CHO DUKX cell lineages preadapted to growth in serum-free suspension culture enable rapid development of cell culture processes for the manufacture of recombinant proteins

Using an adaptive strategy, Chinese hamster ovary (CHO) cell lines were developed that are capable of robust growth in serum-free suspension culture. These preadapted derivatives of the commonly used strain of CHO cells (CHO DUKX), termed PA-DUKX, were used for the introduction and stable expression of several heterologous human genes. A significant advantage of recombinant PA-DUKX cells was their ability to readily resume growth in serum-free suspension culture after transfection and amplification of heterologous genes. Expression of recombinant human proteins in PA-DUKX cells was quantitatively similar to that of lineages generated using conventional CHO DUKX cells. In addition, recombinant human proteins expressed by transfected PA-DUKX lineages were shown to be biochemically and structurally similar to those expressed in CHO DUKX cells, PA-DUKX host cell technology provides an opportunity for reducing the time and resources required to develop large-scale, suspension culture-based manufacturing processes employing serum-free medium. (c) 1996 John Wiley & Sons, Inc.     

Transient Transfection Factors for High-Level Recombinant Protein Production in Suspension Cultured Mammalian Cells

The efficient transfection of cloned genes into mammalian cells system plays a critical role in the production of large quantities of recombinant proteins (r-proteins). In order to establish a simple and scaleable transient protein production system, we have used a cationic lipid-based transfection reagent-FreeStyle MAX to study transient transfection in serum-free suspension human embryonic kidney (HEK) 293 and Chinese hamster ovary (CHO) cells. We used quantification of green fluorescent protein (GFP) to monitor transfection efficiency and expression of a cloned human IgG antibody to monitor r-protein production. Parameters including transfection reagent concentration, DNA concentration, the time of complex formation, and the cell density at the time of transfection were analyzed and optimized. About 70% GFP-positive cells and 50-80 mg/l of secreted IgG antibody were obtained in both HEK-293 and CHO cells under optimal conditions. Scale-up of the transfection system to 1 l resulted in similar transfection efficiency and protein production. In addition, we evaluated production of therapeutic proteins such as human erythropoietin and human blood coagulation factor IX in both HEK-293 and CHO cells. Our results showed that the higher quantity of protein production was obtained by using optimal transient transfection conditions in serum-free adapted suspension mammalian cells.     

犬肾细胞MDCK无血清贴壁及单细胞悬浮培养

旨在挖掘用于鉴定金黄色葡萄球菌的高特异性靶点及其PCR检测引物。采用C++语言编程,以金黄色葡萄球菌Staphylococcus aureus MRSA 252基因组编码序列为对象,对2 656个可编码区进行分析,获得特异性靶点序列,并设计PCR扩增引物。对包括葡萄球菌属11个种及其他细菌属在内的共计137株细菌验证引物特异性,筛选获得9个DNA序列,并设计了4对引物。经验证2对引物的特异性较好,其中引物SA3的基因组DNA检测限为13.7 fg/μL,菌体检测限为9.25×102 CFU/mL。结果验证